本帖最后由 lkf1002 于 2012-10-27 22:12 編輯
我把重點根據(jù)我的理解稍微翻譯一下：
2013年在中國進入臨床實驗，呵呵，誰申請去當小白鼠呀。
MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China
May 7, 2012 11:26 am
中國有個 NovoTek Therapeutics Inc. 的公司跟 加拿大的MaRs 合作
ScarX logoMaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐\\\develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.
這幾個合作的組織開發(fā)了一種祛除手術(shù)后疤痕的藥物，然后投入到中國市場。
This project was covered in The Globe and Mail on May 7, 2012.
For many people, developing excessive scar tissue growth after surgery can cause physical discomfort along with emotional and psychological stress. Each year, approximately 240 million surgeries are performed worldwide. Market research suggests an effective anti‐\\\skin‐\\\scarring therapeutic represents a multi-billion dollar opportunity.
Currently, no clinically-proven prescription therapeutic can prevent excessive dermal scarring.
Recognizing this promising treatment’s value and the challenging financing environment for preclinical stage therapeutics, MI initiated a co-development licensing option agreement with NovoTek. Based in Beijing, China, NovoTek will be responsible for development and commercialization costs for the anti‐\\\scarring medication in the Chinese market.
MI and SickKids will receive clinical development milestone payments from NovoTek; MI will also have access to all preclinical and clinical data generated by NovoTek to support future clinical development for strategic markets outside China, including the United States, Canada, Brazil and Korea.
“With a proven track record in clinical development in China and strong ties to the Ontario research community, we believe that NovoTek and its founder, Dr. Jubo Liu, are ideal partners for MaRS Innovation and SickKids to co‐\\\develop, and ultimately commercialize, the anti-scarring therapeutic in the Chinese marketplace and eventually in other territories,” stated Raphael Hofstein, president and CEO of MaRS Innovation.
Dr. Benjamin Alman, head of the Division of Orthopaedic Surgery and senior scientist, Program in Developmental and Stem Cell Biology at SickKids, discovered that a particular molecule known for its analgesic properties could effectively target myofibroblast cells — the cells responsible for producing scar tissue.
Dr. Benjamin Alman 這個藥物的發(fā)明人，發(fā)現(xiàn)了一種特別的分子可以對抗產(chǎn)生疤痕的肌纖維母細胞。
Alman and his team have successfully developed an alternative use for this molecule as an anti‐\\\scarring medication. ScarX, a topical cream containing this molecule, can reduce scarring when applied to a surgical wound, as demonstrated in gold-standard preclinical models.
Alam 已經(jīng)找到了這個分子的替代品，制成名叫ScarX 的藥膏。
Clinical trials are expected to begin in early 2013.
這個藥膏在2013年開始臨床實驗。
“We have a good understanding of which cells are responsible for producing scar tissue during the wound healing process,” says Alman. “The real challenge has been stopping those specific cells from making excessive amounts of scar tissue without negatively impacting the overall wound healing process. This therapeutic cream appears to do exactly that.”
我們都知道在傷口愈合過程中，是什么引起了疤痕，我們真正的挑戰(zhàn)來自于是在不影響疤痕縫合的前提下，阻止疤痕的形成。
“NovoTek is thrilled to partner with MI and SickKids to address this unmet clinical need by furthering the development of this anti-scarring product and eventually bringing it to the Chinese marketplace,” says Liu, CEO of NovoTek Therapeutics Inc.
這款產(chǎn)品將進入中國市場。
Alman is the A.J. Latner professor and chair of Orthopaedics at the University of Toronto, vice-chair research of the department of Surgery, and the interim head of the Toronto Musculoskeletal Center. He is also a Canada Research Chair.
|
粵公網(wǎng)安:44030502002385號
發(fā)表于 2012-10-27 21:55:18
QQ好友和群
收藏
分享
加油
反對
提升卡
置頂卡
沉默卡
喧囂卡
變色卡
搶沙發(fā)
千斤頂
狗仔卡
發(fā)表于 2012-10-27 21:58:03
樓主
發(fā)表于 2012-10-28 10:39:16
